Rona Therapeutics, a clinical stage platform company based in Shanghai, China, raised $35 million in Series A+ funding. The company specialises in nucleic acid medication research and development.
LongRiver Investments headed the round, and both new and old international investment funds participated.
The funding will be used by the company to advance metabolic siRNA pipeline programmes into global development and to extend its extra-hepatic delivery platform into the central nervous system and other areas.
Rona Therapeutics is an innovative nucleic acid therapeutic platform firm that specialises in treating metabolic illnesses and CNS degenerative diseases.
Read also- Israel-Based CTERA Secures $80 Million in Primary and Secondary Funding
The company is led by Ms Stella SHI, who also serves as CEO. Rona is developing a siRNA programme pipeline using a next-generation siRNA platform. The first programme of the company, RN0191, a best-in-class PCSK9 siRNA programme, has finished Ph1 clinical investigations in Australia and China and is prepared for Ph2 clinical development for hypercholesterolemia.
Read also- India-Based Fibr Secures $1.8 Million in Seed Funding
The company’s second programme for hypertriglyceridemia, RN0361, is scheduled to go into clinic in 2024Q2. Additionally, Rona is developing novel pipelines at the IND enabling stage for disorders related to obesity, renal disease, and cardiometabolism.
About Rona Therapeutics
Rona Therapeutics is a pioneering RNA therapeutics platform firm that discovers and develops modular and programmable RNA medications for global patients. The company was created by industry veterans with extensive RNA treatments programme execution experience and world-renowned scientific advisors with RNA biology expertise.
